These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 12577466)

  • 1. [Effect of irbesartan--angiotensin II type I receptor inhibitor on oxidative metabolism of lipids in essential hypertension].
    Svishchenko IeP; Kotsiuruba AV; Mehed' OF; Bukhanevich OM; Radchenko VV; Hula NM
    Fiziol Zh (1994); 2002; 48(6):31-6. PubMed ID: 12577466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of irbesartan, an antagonist of AT-1 receptors for angiotensin II, on L-arginine metabolism in arterial hypertension].
    Kotsiuruba AV; Svishchenko IeP; Bukhanevich OM; Kosiakova HV; Berdyshev AH; Radchenko VV; Mishchenko LA; Hula NM
    Fiziol Zh (1994); 2002; 48(3):22-8. PubMed ID: 12125280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan.
    Kotridis P; Kokkas B; Karamouzis M; Sakadamis G; Kanonidis I; Dadous G; Karantona C; Gouli O; Karadoumanis J; Papadopoulos PC; Papadopoulos CL
    Blood Press; 2002; 11(2):91-4. PubMed ID: 12035877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Irbesartan: a new possibility in the treatment of hypertension].
    Rapi J
    Orv Hetil; 2002 May; 143(21):1187-92. PubMed ID: 12073539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients.
    Chida R; Hisauchi I; Toyoda S; Kikuchi M; Komatsu T; Hori Y; Nakahara S; Sakai Y; Inoue T; Taguchi I
    Hypertens Res; 2015 Nov; 38(11):765-9. PubMed ID: 26178150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.
    Kowala MC; Murugesan N; Tellew J; Carlson K; Monshizadegan H; Ryan C; Gu Z; Kane B; Fadnis L; Baska RA; Beyer S; Arthur S; Dickinson K; Zhang D; Perrone M; Ferrer P; Giancarli M; Baumann J; Bird E; Panchal B; Yang Y; Trippodo N; Barrish J; Macor JE
    J Pharmacol Exp Ther; 2004 Apr; 309(1):275-84. PubMed ID: 14718594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The medicine of the month. Losartan (Cozaar)].
    Scheen AJ
    Rev Med Liege; 1997 May; 52(5):367-9. PubMed ID: 9273640
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G; Fuchs W
    Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
    Schmidt B; Schieffer B
    J Med Chem; 2003 Jun; 46(12):2261-70. PubMed ID: 12773029
    [No Abstract]   [Full Text] [Related]  

  • 10. Problems with interpreting the data in Kassler-Taub et al's article comparing irbesartan and losartan.
    Bunt T
    Am J Hypertens; 1999 Jan; 12(1 Pt 1):79-81. PubMed ID: 10075390
    [No Abstract]   [Full Text] [Related]  

  • 11. Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension.
    Taguchi I; Toyoda S; Takano K; Arikawa T; Kikuchi M; Ogawa M; Abe S; Node K; Inoue T
    Hypertens Res; 2013 Jul; 36(7):608-13. PubMed ID: 23425956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Irbesartan--antihypertensive treatment in patients with heart failure and diabetes mellitus].
    Zukowska-Szczechowska E; Gosek K; Grzeszczak W
    Przegl Lek; 2002; 59(3):160-4. PubMed ID: 12184030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    Ceriello A; Motz E
    N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873779
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors.
    Germanò G; Sanguigni V; Pignatelli P; Caccese D; Lenti L; Ragazzo M; Lauro R; Violi F
    J Hypertens; 2004 Jun; 22(6):1151-6. PubMed ID: 15167450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of angiotensin II type 1 receptor antagonist on oxidative stress markers in type 2 diabetic patients with hypertension].
    Sato N; Kase H; Kato T; Kasai K
    Nihon Rinsho; 2003 Jul; 61(7):1245-9. PubMed ID: 12877092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of angiotensin receptor blockers on hemodynamic aspects during myocardial infarction].
    Turubarova NA; Leunov VV; Tashchuk VK
    Lik Sprava; 2002; (3-4):43-4. PubMed ID: 12145889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
    Ruilope L
    J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptors and angiotensin II receptor antagonists.
    Timmermans PB; Wong PC; Chiu AT; Herblin WF; Benfield P; Carini DJ; Lee RJ; Wexler RR; Saye JA; Smith RD
    Pharmacol Rev; 1993 Jun; 45(2):205-51. PubMed ID: 8372104
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
    MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910830
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.